Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Public ClinicalTrials.gov record NCT02983799. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.
Study identification
- NCT ID
- NCT02983799
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 22, 2016 (Actual)
- Primary completion
- Dec 3, 2020 (Actual)
- Completion
- Dec 3, 2020 (Actual)
- Last update posted
- Apr 13, 2022
2016 – 2020
United States locations
- U.S. sites
- 35
- U.S. states
- 23
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99508 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90017 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Hartford | Connecticut | 06102 | — |
| Research Site | New Haven | Connecticut | 06519 | — |
| Research Site | Newark | Delaware | 19718 | — |
| Research Site | South Miami | Florida | 33143 | — |
| Research Site | Skokie | Illinois | 60077 | — |
| Research Site | Shreveport | Louisiana | 71103 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Springfield | Massachusetts | 01199 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | Saint Paul | Minnesota | 55125 | — |
| Research Site | Berkeley Heights | New Jersey | 07922 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | Newark | New Jersey | 07103 | — |
| Research Site | Teaneck | New Jersey | 07666 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Portland | Oregon | 97227 | — |
| Research Site | Abington | Pennsylvania | 19001 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Pittsburgh | Pennsylvania | 15224 | — |
| Research Site | Providence | Rhode Island | 02905 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Annandale | Virginia | 22003 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02983799, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02983799 live on ClinicalTrials.gov.